Ketamine for acute suicidal ideation. An emergency department intervention: A randomized, double-blind, placebo-controlled, proof-of-concept trial
Depression and Anxiety Jan 11, 2020
Domany Y, et al. - Researchers here examined if ketamine, a rapidly acting antidepressant with antisuicidal properties, might offer relief to depressed patients presenting to emergency departments with acute suicidal ideation. They conducted a randomized, double-blind, placebo-controlled, proof-of-concept trial randomizing 18 depressed individuals with acute suicidal ideation, who needed hospitalization, to either an intravenous ketamine 0.2 mg/kg group or a saline placebo group. Remission of suicidal ideation was achieved in 88% of the ketamine group vs 33% in the placebo group at 90 minutes after infusion. Outcomes suggest that for depressed, highly suicidal individuals presenting to the emergency department, ketamine is safe and effective for rapid reduction in suicidal ideation.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries